Tests a cell therapy with add-on drugs in relapsed or resistant multiple myeloma
Tests a cell therapy combined with other drugs in adults with returned or resistant myeloma.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Key facts
- Where
- Calgary and Toronto, CanadaSee the 2 sites
- Phase
- Phase 1
Where in Canada
- Arthur J.E. Child Comprehensive Cancer CentreCalgary, CanadaTaking people
- Princess Margaret Cancer CentreToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Trial code
- NCT06121843
- Record updated
- 16 July 2026
- Original description
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).Read full original descriptionShow less
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).
Inclusion: History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1), history of RRMM or at least 1 but not greater than 3 prior anti-myeloma treatment (PAMT) regimens (Part 2, Arms A, B, C, and D); history of quadruple class exposed RRMM having received BCMA TCE as the most recent line of therapy (Part 2, Arm E); Measurable multiple myeloma (MM) as per International Myeloma Working Group (IMWG); Eastern Cooperative Oncology Group performance status of 0-1; Adherence to contraception requirements.
Exclusion: Prior treatment with alnuctamab (Arm A), mezigdomide (Arms B and E), iberdomide (Arm C), elranatamab (Arm D) or BCMA-targeting therapy (Part 2 Arms A and D); Prior treatment with GPRC5D-targeting therapies as of Protocol Amendment 02 (Part 1 and Part 2); Other protocol-defined inclusion/exclusion criteria apply.